Home
中文
About Us
> CEO Statement
> At a Glance
> Mission and Values
> Global Recognition
> History and Milestones
> Management Team
> Brochure
Therapeutic Focus
> Oncology
> Autoimmune Diseases
Products
> Pipeline Overview
> HMPL-004
> HMPL-011
> HMPL-012
> HMPL-013
> HMPL-813
Research & Development
> Drug Discovery Research
> Drug Development
> Facility and Capacity
Collaborations
> Overview
> Existing Partnerships
Media
> Key Facts
> Press Releases
> Featured Articles
Careers
Contacts
Press Releases
05/25/2010
Hutchison MediPharma and the Committee of Anti-Cancer Agent Successfully Jointly Hold the First Targeted Anti-Cancer Drug Research and Development Symposium
05/06/2010
Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer
03/09/2010
HMPL-004 Ulcerative Colitis Results Selected for Distinguished Plenary Oral Presentation during Digestive Disease Week Conference
11/05/2009
Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved, Proceeding with Development and Partnership Plans
10/30/2009
Initiated Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Autoimmune Diseases
07/29/2009
Completed Patient Enrollment Ahead of Schedule for HMPL-004’s Global Phase IIb Trial for Ulcerative Colitis
07/28/2009
HMPL-012 (Sulfatinib) Receives Grant Support from Science and Technology Commission of Shanghai Municipality
07/13/2009
Hutchison MediPharma Announces Encouraging Results from Crohn's Disease Phase II Trial for HMPL-004
06/23/2009
Dr. Samantha Du Attends ChinaBio’s First Ever Partnering Forum as Keynote Panel Speaker
06/06/2009
Hutchison MediPharma Awarded “2009 China’s Most Innovative Enterprise”
First Prev
Next
Last
CountPage：1/5 RecordCount：42
Top
Back home
Print page
